AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23001642 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based diabetes and nutritional intervention
Number of subjects: 180
Study 19755938 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1.0 microg/kg)
Number of subjects: 24
Study 19755938 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (3 mL)
Number of subjects: 24
Study 17322145 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily mesalazine (1 x 4 g/d)
Number of subjects: 30
Study 17322145 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily mesalazine (2 x 2 g/d)
Number of subjects: 30
Study 15451744 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard group
Number of subjects: 3081
Study 15451744 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced group
Number of subjects: 3081
Study 15451744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3081
Study 11882333 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day TRF25
Number of subjects: 90
Study 11882333 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day TRF25
Number of subjects: 90
Study 11882333 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day TRF25
Number of subjects: 90
Study 11882333 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day TRF25
Number of subjects: 90
Study 11882333 — intervention group
Group type: COMPARATOR
Intervention: AHA Step‐1 diet
Number of subjects: 90
Study 9835980 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg.kg‐1, IM)
Number of subjects: 8
Study 9835980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9160577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 43
Study 9160577 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 43
Study 9160577 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 43
Study 2492286 — intervention group
Group type: EXPERIMENTAL
Intervention: No plaster cast or weight-bearing, and active exercises of the ankle
Number of subjects: 56
Study 2492286 — intervention group
Group type: COMPARATOR
Intervention: Non-weight-bearing plaster cast
Number of subjects: 56
Study 2492286 — intervention group
Group type: COMPARATOR
Intervention: Plaster walking cast for the first six postoperative weeks
Number of subjects: 56
Study 1107512 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 279
Study 1107512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 31482797 — intervention group
Group type: COMPARATOR
Intervention: Normal night's sleep
Number of subjects: 12
Study 31482797 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sleep deprivation
Number of subjects: 12
Study 31482797 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-blink parameters
Number of subjects: 12
Study 28923223 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment modalities for hepatocellular carcinoma
Number of subjects: 0
Study 26228892 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (n = 31)
Number of subjects: 133
Study 26228892 — intervention group
Group type: COMPARATOR
Intervention: Low-osmolal contrast media (n = 102)
Number of subjects: 133
Study 23787519 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 138
Study 23787519 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 138
Study 21753916 — intervention group
Group type: EXPERIMENTAL
Intervention: IRx intervention in NICU trial
Number of subjects: 299
Study 21753916 — intervention group
Group type: COMPARATOR
Intervention: Routine information services (control) in NICU trial
Number of subjects: 299
Study 21753916 — intervention group
Group type: COMPARATOR
Intervention: Routine information services (control) in BrCa trial
Number of subjects: 299
Study 18850117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% zinc citrate dentifrice
Number of subjects: 30
Study 18850117 — intervention group
Group type: COMPARATOR
Intervention: Control formulation
Number of subjects: 30
Study 16764620 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 41
Study 16764620 — intervention group
Group type: EXPERIMENTAL
Intervention: LycoRed (2000 microg lycopene)
Number of subjects: 41
Study 15218558 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium softgel
Number of subjects: 75
Study 15218558 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac potassium (Cataflam)
Number of subjects: 75
Study 15218558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10845671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone-primed IFN treatment (Group I)
Number of subjects: 85
Study 10845671 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN treatment only (Group II)
Number of subjects: 85
Study 10845671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 85
Study 9120464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 25
Study 9120464 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study 1302763 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.4 mg iv prednisolone
Number of subjects: 7
Study 1302763 — intervention group
Group type: EXPERIMENTAL
Intervention: 49.2 mg iv prednisolone
Number of subjects: 7
Study 1302763 — intervention group
Group type: COMPARATOR
Intervention: No drug (baseline)
Number of subjects: 7
Study 3886139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac (100 mg QID)
Number of subjects: 30
Study 3886139 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg QID)
Number of subjects: 30
Study 30316139 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline social support quality (positive support, negative interactions, conflict)
Number of subjects: 316
Study 30316139 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline social support quality
Number of subjects: 316
Study 30316139 — intervention group
Group type: COMPARATOR
Intervention: Baseline social support
Number of subjects: 316
Study 30020124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer-assisted planning
Number of subjects: 40
Study 30020124 — intervention group
Group type: COMPARATOR
Intervention: 2D planning
Number of subjects: 40
Study 30020124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D planning
Number of subjects: 40
Study 28659429 — intervention group
Group type: EXPERIMENTAL
Intervention: EVD plus intraventricular alteplase
Number of subjects: 500
Study 28659429 — intervention group
Group type: COMPARATOR
Intervention: EVD plus saline
Number of subjects: 500
Study 26149802 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 622
Study 22892722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose chest computed tomography (ULD-CT) with model-based iterative reconstruction (MBIR)
Number of subjects: 42
Study 22892722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose chest computed tomography (ULD-CT)
Number of subjects: 42
Study 22892722 — intervention group
Group type: COMPARATOR
Intervention: Standard dose diagnostic CT (SDD-CT)
Number of subjects: 42
Study 22892722 — intervention group
Group type: COMPARATOR
Intervention: Low-dose diagnostic CT (LDD-CT)
Number of subjects: 42
Study 20651284 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM)
Number of subjects: 80
Study 20651284 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial miR-126 in diabetic patients
Number of subjects: 80
Study 20651284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic Lep(ob) mice
Number of subjects: 80
Study 20651284 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose concentrations
Number of subjects: 80
Study 20651284 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 80
Study 18262655 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 46
Study 18262655 — intervention group
Group type: COMPARATOR
Intervention: ECT
Number of subjects: 46
Study 16841343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg)
Number of subjects: 60
Study 16841343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 1-week run-in)
Number of subjects: 60
Study 12681451 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 79
Study 12681451 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 79
Study 10097028 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 18
Study 10097028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11321183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy at high dose (600 mg ZDV/6 MIU IFN‐alpha)
Number of subjects: 34
Study 11321183 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) and interferon‐alpha (IFN‐alpha) combination therapy
Number of subjects: 34
Study 11321183 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alpha (IFN‐alpha) monotherapy
Number of subjects: 34
Study 11321183 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 34
Study 1816245 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic blood transfusion
Number of subjects: 0
Study 1816245 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusion therapy
Number of subjects: 0
Study 1816245 — intervention group
Group type: EXPERIMENTAL
Intervention: Excellent prenatal monitoring and aggressive intervention
Number of subjects: 0
Study 1816245 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal diagnosis and cord blood screening
Number of subjects: 0
Study 1816245 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin
Number of subjects: 0
Study 6109857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg daily)
Number of subjects: 20
Study 6109857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31296157 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI cases (n=7)
Number of subjects: 84
Study 31296157 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI prediction
Number of subjects: 84
Study 28558695 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 1018
Study 28558695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 1018
Study 26392160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass oral azithromycin distribution
Number of subjects: 0
Study 26392160 — intervention group
Group type: COMPARATOR
Intervention: Expert survey estimation
Number of subjects: 0
Study 26392160 — intervention group
Group type: COMPARATOR
Intervention: Bayesian analysis
Number of subjects: 0
Study 23963850 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration and intracoronary tirofiban
Number of subjects: 80
Study 23963850 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 80
Study 21277016 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg daily
Number of subjects: 20536
Study 21277016 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20536
Study 19372044 — intervention group
Group type: EXPERIMENTAL
Intervention: RITA used in Y-graft configuration
Number of subjects: 0
Study 16569552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification group (LG)
Number of subjects: 101
Study 16569552 — intervention group
Group type: COMPARATOR
Intervention: Advice group (Control)
Number of subjects: 101
Study 16569552 — intervention group
Group type: EXPERIMENTAL
Intervention: *825T allele carriers in LG
Number of subjects: 101
Study 12473420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified diet counseling
Number of subjects: 715
Study 12473420 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 715
Study 10693368 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine 500 mg three times daily
Number of subjects: 98
Study 10693368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8252691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation with alpha-tocopherol (800 IU/d), ascorbate (1.0 g/d), and beta carotene (30 mg/d)
Number of subjects: 24
Study 8252691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8252691 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol only (800 IU/d)
Number of subjects: 24
Study 3099269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli-containing formula
Number of subjects: 30
Study 3099269 — intervention group
Group type: COMPARATOR
Intervention: Non-lactobacilli-containing formula
Number of subjects: 30
Study 30145512 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439
Study 30145512 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 30145512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Cognitive-Behavioral Therapy and Fluoxetine (COMB)
Number of subjects: 439
Study 26867045 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling intervention based on self-determination theory (SDT)
Number of subjects: 67
Study 26867045 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 67
Study 24961881 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of caries-free children
Number of subjects: 981
Study 24961881 — intervention group
Group type: COMPARATOR
Intervention: Parents of children with caries
Number of subjects: 981
Study 22490589 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg over 10 minutes, maintenance dosage 0.7 µg×kg(‐1)×h(‐1))
Number of subjects: 60
Study 22490589 — intervention group
Group type: COMPARATOR
Intervention: Propofol target-controlled infusion
Number of subjects: 60
Study 20473244 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm use (immediate)
Number of subjects: 140
Study 20473244 — intervention group
Group type: COMPARATOR
Intervention: Observation before commencing diaphragm use (delayed)
Number of subjects: 140
Study 18705232 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-thickness skin grafts
Number of subjects: 100
Study 18705232 — intervention group
Group type: COMPARATOR
Intervention: Conservative wound dressing
Number of subjects: 100
Study 15978305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheniramine maleate 0.3%/naphazoline hydrochloride 0.025% ophthalmic solution
Number of subjects: 83
Study 15978305 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 83
Study 15978305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 12416598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day of risperidone
Number of subjects: 49
Study 12416598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day of risperidone
Number of subjects: 49
Study 12416598 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 49
Study 10599225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin (200-600 micrograms/day subcutaneously)
Number of subjects: 30
Study 10599225 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs used in acute destructive pancreatitis
Number of subjects: 30
Study 8773866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 22
Study 8773866 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Number of subjects: 22
Study 8773866 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 22
Study 1481179 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg) with placebo pretreatment
Number of subjects: 10
Study 1481179 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg) with indomethacin pretreatment
Number of subjects: 10
Study 1481179 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation with placebo pretreatment
Number of subjects: 10
Study 1481179 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation with indomethacin pretreatment
Number of subjects: 10
Study 6361565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 59
Study 6361565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 59
Study 6361565 — intervention group
Group type: COMPARATOR
Intervention: Control (19 healthy women)
Number of subjects: 59
Study 31492788 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategy behavioural intervention integrated into the existing online canteen system, utilizing choice architecture strategies such as menu labelling, placement, prompting, and provision of feedback and incentives.
Number of subjects: 26
Study 31492788 — intervention group
Group type: COMPARATOR
Intervention: Standard online canteen ordering system (control group).
Number of subjects: 26
Study 29498342 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement
Number of subjects: 88
Study 29498342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24686745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Back Activity Confidence Scale (LoBACS)
Number of subjects: 112
Study 24982459 — intervention group
Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of plasmacytoid dendritic cells (pDCs)
Number of subjects: 308
Study 24982459 — intervention group
Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of naïve CD8(+) T cells (CD8Tns)
Number of subjects: 308
Study 24982459 — intervention group
Group type: EXPERIMENTAL
Intervention: BM allografts with > median number of naïve CD4(+) T cells (CD4Tns)
Number of subjects: 308
Study 24982459 — intervention group
Group type: EXPERIMENTAL
Intervention: BM allografts with more T cells
Number of subjects: 308
Study 24982459 — intervention group
Group type: EXPERIMENTAL
Intervention: BM allografts with more pDCs
Number of subjects: 308
Study 24982459 — intervention group
Group type: COMPARATOR
Intervention: PB grafts
Number of subjects: 308
Study 23129084 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based preventive care program (9 home visits over the first year)
Number of subjects: 120
Study 23129084 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 120
Study 19781700 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg vaginally every 4 hours for up to 72 hours
Number of subjects: 50
Study 18622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 mcg once daily
Number of subjects: 353
Study 18622139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 18622139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 353
Study 15767334 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (3 g daily, providing 1,200 mg of calcium)
Number of subjects: 672
Study 15767334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 11831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional stimulus classes established using a task with nonsense words and symbols, assessed with transfer-of-function test and follow-up test.
Number of subjects: 0
Study 11831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus equivalence classes established with computerized matching-to-sample procedures, assessed with postreversal equivalence test and follow-up test.
Number of subjects: 0
Study 11831781 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up performances after reversals.
Number of subjects: 0
Study 10524689 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNFα monoclonal antibody treatment
Number of subjects: 0
Study 7733079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa (1 g/day)
Number of subjects: 52
Study 7733079 — intervention group
Group type: COMPARATOR
Intervention: Cortenema (100 mg/day)
Number of subjects: 52
Study 1345695 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative artificial feeding (enteral or parenteral) for 7 to 15 days
Number of subjects: 0
Study 1345695 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative artificial feeding
Number of subjects: 0
Study 1345695 — intervention group
Group type: COMPARATOR
Intervention: Enteral feeding
Number of subjects: 0
Study 1345695 — intervention group
Group type: EXPERIMENTAL
Intervention: New substrates (structured lipids, glutamine, trace elements)
Number of subjects: 0
Study 6651352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 ppm ozone exposure
Number of subjects: 28
Study 6651352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm ozone exposure
Number of subjects: 28
Study 6651352 — intervention group
Group type: COMPARATOR
Intervention: 0.0 ppm ozone exposure (control)
Number of subjects: 28
Study 31781836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ScvO2 monitoring
Number of subjects: 152
Study 31781836 — intervention group
Group type: COMPARATOR
Intervention: Continuous ScvO2 monitoring
Number of subjects: 152
Study 30551689 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-comparison feedback intervention group
Number of subjects: 1421
Study 30551689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback via SMS)
Number of subjects: 1421
Study 29231363 — intervention group
Group type: EXPERIMENTAL
Intervention: Twirling reducing method group (acupuncture at specific acupoints with strong low-frequency twirling reducing method applied at Xiaxi and Taichong)
Number of subjects: 101
Study 29231363 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle retaining group (identical acupoints and needle insertion manipulation without reducing method)
Number of subjects: 101
Study 29231363 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy group (laser and ultrashort wave treatment)
Number of subjects: 101
Study 25064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular paracetamol (3990 mg/day, three times per day)
Number of subjects: 1652